NASDAQ: PPCBPropanc Biopharma Inc Stock
$0.51+0.01 (+2%)
Updated Oct 2, 2026
PPCB Price
$0.51
Fair Value Price
$0.70
Market Cap
$3.21M
52 Week Low
$0.47
52 Week High
$52.50
P/E
-0.03x
P/B
0.34x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$18.86M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.36
Operating Cash Flow
-$6M
Beta
2.69
Next Earnings
Nov 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
PPCB Overview
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer. Propanc Biopharma is also engaged in a collaborative research effort with the University of Jaén, initiating the POP1 joint drug discovery program. Founded in 2007, the entity was originally known as Propanc Health Group Corporation before officially changing its name to Propanc Biopharma, Inc. in April 2017. The company's headquarters are located in Camberwell, Australia.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PPCB's potential to beat the market
- PPCB doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PPCB
RankedUnranked of 461
RankedUnranked of 461
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.51 | A | |
| $8.54 | A | |
| $358.07 | A |
Be the first to know about important PPCB news, forecast changes, insider trades & much more!
PPCB News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PPCB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PPCB ($0.51) is undervalued by 27.3% relative to our estimate of its Fair Value price of $0.70 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
PPCB ($0.51) is significantly undervalued by 27.3% relative to our estimate of its Fair Value price of $0.70 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
PPCB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PPCB due diligence checks available for Premium users.
Valuation
PPCB fair value
Fair Value of PPCB stock based on Discounted Cash Flow (DCF)
Price
$0.51
Fair Value
$0.70
Undervalued by
26.87%
PPCB ($0.51) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PPCB ($0.51) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PPCB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PPCB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.03x
Industry
12.21x
Market
49.66x
PPCB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.34x
Industry
5.04x
PPCB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PPCB's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.6M
Profit Margin
0%
PPCB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$12.8M
Liabilities
$3.4M
Debt to equity
0.36
PPCB's short-term assets ($8.54M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PPCB's short-term assets ($8.54M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PPCB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PPCB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.6M
Investing
-$21.0
Financing
$2.0M
PPCB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PPCB vs Biotech Stocks
Propanc Biopharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.